Protagonist Therapeutics, Inc (PTGX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Protagonist Therapeutics, Inc reported revenue of $46.02M, down 89.4% from the prior year. The company ran a net loss, with a net margin of -282.8%. It held $668.19M in total assets against $53.48M in total liabilities.
Key ratios (FY2025)
-343.6%
Operating margin
-282.8%
Net margin
-21.2%
Return on equity
-89.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $46.02M | $434.43M | $60.00M | $26.58M | $27.36M | $28.63M | $231.0K | $30.93M | $20.06M | — |
| Operating Income | -$158.13M | $252.84M | -$93.65M | -$131.37M | -$125.84M | -$64.52M | -$80.52M | -$42.27M | -$37.90M | -$32.67M |
| Net Income | -$130.15M | $275.19M | -$78.95M | -$127.39M | -$125.55M | -$66.15M | -$77.19M | -$38.92M | -$36.96M | -$37.18M |
| EPS (Diluted) | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 | $-1.92 | — | — | — | — |
| Total Assets | $668.19M | $744.73M | $357.95M | $247.93M | $347.69M | $324.47M | $154.92M | $139.47M | $163.73M | $93.99M |
| Total Liabilities | $53.48M | $69.43M | $21.27M | $32.32M | $47.67M | $44.86M | $74.95M | $26.96M | $43.10M | $6.43M |
| Shareholders' Equity | $614.71M | $675.29M | $336.68M | $215.61M | $300.02M | $279.61M | $79.96M | $112.52M | $120.63M | $87.56M |
| Cash & Equivalents | $128.39M | $97.25M | $186.73M | $125.74M | $123.67M | $117.36M | $33.01M | $82.23M | $106.03M | $21.08M |
| Operating Cash Flow | $57.67M | $184.15M | -$70.24M | -$108.14M | -$107.86M | -$72.48M | -$41.53M | -$49.95M | $3.87M | -$29.97M |
| Capital Expenditures | $1.59M | $1.35M | $609.0K | $795.0K | $1.10M | $471.0K | $967.0K | $486.0K | $666.0K | $347.0K |
| Shares Outstanding | 62.58M | 61.04M | 57.71M | 49.34M | 47.84M | 43.75M | 27.22M | 23.19M | 21.09M | 16.72M |